Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

38.8K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family Functioning and Medication Self-Management in Rural Older Adults With Chronic Comorbidities: The Mediating Role of Self-Efficacy.

Journal of clinical nursing·2026
Same author

Targeted Isolation of Novel Calcium-Binding Peptides via Hydroxyapatite Affinity and Their Promotion Effect on Osteogenesis in MC3T3-E1 Cells.

Journal of food science·2026
Same author

The organelle-targeting duality of nanomaterials: physicochemical property-guided therapeutic effects and toxicological outcomes.

Biochemical pharmacology·2026
Same author

ROS-GS: Relightable Outdoor Scenes With Gaussian Splatting.

IEEE transactions on visualization and computer graphics·2026
Same author

Multiparticle entanglement of nuclear spins in silicon.

Nature communications·2026
Same author

Structural determinants of mucus barrier function: How chondroitin sulfate disaccharide composition modulates mucin binding and permeability.

International journal of biological macromolecules·2026

Related Experiment Video

Updated: Mar 18, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.

Shuyun Yang1, Yingying Chen2, Fulan Sun3

  • 1Department of Pathology, Nantong University Tumor Hospital, Nantong, Jiangsu Province, People's Republic of China.

Archives of Medical Research
|July 10, 2016
PubMed
Summary
This summary is machine-generated.

The p53-induced RING-H2 (PIRH2) protein promotes breast cancer cell proliferation and affects cell cycle progression. Inhibiting PIRH2 reduces tumor growth, offering a potential therapeutic target for breast cancer.

Keywords:
Breast neoplasmsCell cycleProliferationUbiquitinp53-induced RING-H2 (PIRH2)

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

12.8K

Related Experiment Videos

Last Updated: Mar 18, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

12.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • p53-induced RING-H2 (PIRH2) protein is implicated in cellular processes.
  • Understanding PIRH2's role in breast cancer is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the influence of PIRH2 on breast cancer cell proliferation.
  • To analyze the effect of PIRH2 on the cell cycle of breast cancer cells.

Main Methods:

  • PIRH2 expression was assessed using Western blot, IHC, and Kaplan-Meier analysis.
  • Cell proliferation was measured by CCK-8 assays.
  • Cell cycle distribution was analyzed via flow cytometry.

Main Results:

  • PIRH2 was upregulated in breast cancer tissues and cell lines, correlating with poor survival.
  • Inhibition of PIRH2 using siRNA reduced cell proliferation.
  • PIRH2 downregulation increased G0/G1 phase cells, without significantly affecting G2/M phase.

Conclusions:

  • Decreased PIRH2 expression inhibits breast cancer cell growth by reducing proliferation and disrupting cell cycle transition.
  • PIRH2 represents a potential therapeutic target for breast cancer treatment.